title: Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
abstract: Immunotherapy such as nivolumab is a new promising therapeutic option for advanced stage non small cell lung cancer (NSCLC). Due to the interference with the immune system previously unknown side effects are observed both in clinical studies and experience. Autoimmune phenomena effecting skin, gastrointestinal tract, endocrine glands, kidney and lung have been described. Up to now there is only limited information regarding potential cardiac side effects. We present a case of symptomatic drug induced myocarditis after nine cycles of nivolumab in a patient with efficient anticancer response.
authors: ELK Thorax Center, Lindenberger Weg 27, 13125 Berlin, Germany.
authors: H
authors: H
authors: Semper
authors: Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center, A Joint Cooperation Between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine and HELIOS Hospital Berlin Buch, Department of Cardiology and Nephrology, Schwanebecker Chaussee 50, 13125 Berlin, Germany.
authors: F
authors: F
authors: Muehlberg
authors: Working Group on Cardiovascular Magnetic Resonance, Experimental and Clinical Research Center, A Joint Cooperation Between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine and HELIOS Hospital Berlin Buch, Department of Cardiology and Nephrology, Schwanebecker Chaussee 50, 13125 Berlin, Germany.
authors: J
authors: J
authors: Schulz-Menger
authors: ELK Thorax Center, Lindenberger Weg 27, 13125 Berlin, Germany.
authors: M
authors: M
authors: Allewelt
authors: ELK Thorax Center, Lindenberger Weg 27, 13125 Berlin, Germany. Electronic address: Christian.grohe@pgdiakonie.de.
authors: C
authors: C
authors: Grohé
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects* / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D009205:Myocarditis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D009367:Neoplasm Staging; D000077594:Nivolumab; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D000077594:Nivolumab
keywords: Drug-induced myocarditis; Immunotherapy; Nivolumab; PDL-1; Pulmonary squamous cell carcinoma